Anixa Biosciences has announced that the Korean Ministry of Intellectual Property has granted a composition-of-matter patent for its breast cancer vaccine technology.

• Patent Protection: Patent Number 10-2960889 provides protection for the company’s breast cancer prevention and treatment technology in South Korea through 2040.
• Technology Licensing: The patented technology is exclusively licensed from Cleveland Clinic and supports Anixa’s breast cancer vaccine programme.
• Intellectual Property: The Korean patent expands Anixa’s international intellectual property portfolio and complements its existing patent protection in the United States and other international markets.

This summary is based on a news report published by BioSpectrum Asia.

Image for illustrative purposes only. Source: Canva.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.